Kingsview Wealth Management’s iShares Biotechnology ETF IBB Stock Holding History

Kingsview Wealth Management’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200	Closed	-$26K	–	930
2021 Q4	$26K	Buy	+200	New	+$31K	﹤0.01%	924
2021 Q2	–	Sell	-400	Closed	-$1K	–	953
2021 Q1	$1K	Buy	+400	New	+$63.5K	﹤0.01%	848
2017 Q2	–	Sell	-3,300	Closed	-$4K	–	373
2017 Q1	$4K	Buy	+3,300	New	+$316K	﹤0.01%	262

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.9% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Kingsview Wealth Management's IBB Position: Q2 2026 in Review

Kingsview Wealth Management increased its iShares Biotechnology ETF (IBB) stake by 5.3% in Q2 2026, buying an estimated $33K and bringing the position to 3,833 shares worth $729K. The position accounts for 0.01% of the portfolio, ranked #845.

Kingsview Wealth Management first reported a position in IBB in Q1 2017 and has held it in 38 quarters since. The position peaked at $4.24M in Q4 2024. 960 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Kingsview Wealth Management held 3,833 shares of iShares Biotechnology ETF worth $729K as of Q2 2026.
Kingsview Wealth Management bought 192 iShares Biotechnology ETF shares in Q2 2026, an estimated $33K.
iShares Biotechnology ETF made up 0.01% of Kingsview Wealth Management's portfolio in Q2 2026, its #845 holding.
Kingsview Wealth Management first reported a position in iShares Biotechnology ETF in Q1 2017 and has held it in 38 quarters since.
Kingsview Wealth Management's iShares Biotechnology ETF position peaked at $4.24M in Q4 2024.
960 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.